Annex Advisory Services LLC Purchases 9,435 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Annex Advisory Services LLC grew its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 213.2% in the 4th quarter, Holdings Channel.com reports. The firm owned 13,860 shares of the company’s stock after acquiring an additional 9,435 shares during the period. Annex Advisory Services LLC’s holdings in Amphastar Pharmaceuticals were worth $857,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in AMPH. McGlone Suttner Wealth Management Inc. purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth approximately $28,000. Principal Securities Inc. purchased a new position in Amphastar Pharmaceuticals in the 4th quarter worth approximately $34,000. Quadrant Capital Group LLC raised its holdings in Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after acquiring an additional 223 shares during the last quarter. Covestor Ltd raised its holdings in Amphastar Pharmaceuticals by 859.0% in the 3rd quarter. Covestor Ltd now owns 1,966 shares of the company’s stock worth $90,000 after acquiring an additional 1,761 shares during the last quarter. Finally, Nisa Investment Advisors LLC raised its holdings in Amphastar Pharmaceuticals by 115.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock worth $150,000 after acquiring an additional 1,300 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH traded down $0.18 during trading hours on Wednesday, reaching $42.04. The company had a trading volume of 478,077 shares, compared to its average volume of 428,214. Amphastar Pharmaceuticals, Inc. has a 52 week low of $38.43 and a 52 week high of $67.66. The firm’s 50 day moving average price is $41.89 and its 200-day moving average price is $49.87. The company has a current ratio of 2.18, a quick ratio of 1.72 and a debt-to-equity ratio of 0.88. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 14.55, a PEG ratio of 0.87 and a beta of 0.82.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. The firm had revenue of $171.84 million during the quarter, compared to the consensus estimate of $171.13 million. On average, analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.6 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on AMPH shares. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, May 22nd. Finally, StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, May 13th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.